| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
iRhythm Holdings, Inc.$116.13
-1.79 (-1.51%)
F 17Pipeline Score MedTech · Commercial
Market Cap
3.83 B
EPS
-0.86
P/E Ratio
-
Value Trade
67.80 M
SEC Financials
Q1 2026Dilution Risk
Revenue
199.39 M
R&D Expenses
21.36 M
Operating CF
-26.17 M
Total Assets
1.01 B
Total Liabilities
845.15 M
Equity
161.21 M
D/E Ratio
12,345
1.94 %
Week
-2.79 %
1 Month
-24.97 %
3 Month
-31.1 %
6 Month
51.06 %
5 Year
335.74 %
All Time
Cash Data
Cash Position
549.62 M
Monthly Burn
8.72 M
Runway
60.9 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
478.54 K
52 Week Range
108.81 - 212
% held by Insiders
1.78 %
% held by Institutions
108.41 %
Enterprise Value
4.01 B
Total Shares
32.30 M
Short %
10.19 %
Float Shares
31.75 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 15%
Small Cap (rank 775 of 911)
Percentile RankiRhythm Holdings, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IRTC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IRTC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IRTC▲ +7%on this news
Three Months Ended
iRhythm Holdings, Inc. announced its financial results for the first quarter of 2026, showing significant growth with a revenue increase of 25.7% compared to the previous year. The gross margin also improved to 70.9%, a positive sign of operational efficiency. Despite these gains, the company still reported a net loss of $13.9 million. Looking forward, iRhythm has raised its revenue guidance for the year to between $875 million and $885 million, underlining confidence in ongoing demand for its services.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (continued) (In thousands) (Unaudited) Three Months Ended December 31, Year Ended December 31, Adjusted operating expenses reconciliatio
iRhythm Holdings announced its financial results for Q4 and the full year 2025, showcasing significant revenue growth and the first positive GAAP net income in its history. The company's revenue for Q4 reached $208.9 million, up 27.1% year-over-year, while full-year revenue rose to $747.1 million. Despite these gains, iRhythm reported a net loss of $44.6 million for the year, though this marked an improvement compared to the previous year. Overall, the results indicate a strong demand for iRhythm's Zio services and effective cost management, setting a positive outlook for 2026.
Read more →IRTCThree Months Ended September 30, Nine Months Ended
iRhythm Technologies, Inc. reported its financial results for the third quarter of 2025, highlighting a significant revenue increase of 30.7% year-over-year to $192.9 million. The company's gross margin improved to 71.1%, indicating better operational efficiencies and cost management. Additionally, iRhythm has increased its fiscal year 2025 revenue guidance, reflecting strong demand for its Zio services. However, the company still reported a net loss of $5.2 million, although this marks a substantial improvement compared to the previous year.
Read more →IRTCThree Months Ended June 30, Six Months Ended
iRhythm Technologies, Inc. reported strong financial results for the second quarter of 2025, with revenue of $186.7 million, a 26.1% increase from the same quarter in 2024. The gross margin improved to 71.2%, benefiting from operational efficiencies. The company has partnered with Lucem Health to advance early detection of arrhythmias, while maintaining guidance for total revenue of $720 to $730 million for the fiscal year 2025. However, operating expenses also rose, leading to a net loss of $14.2 million despite the overall positive growth trajectory.
Read more →IRTCAdjusted net income (loss) reconciliation* Net loss, as reported 1 $ (1,333) $ (38,699) $ (113,289) $ (123,406) Impairment charges - 11,078 641 11,078 Business transformation costs 2,416 1,772 11,072 15,866 Changes in fa
iRhythm Technologies, Inc. reported its financial results for Q4 and full year 2024, showcasing significant revenue growth and operational improvements. The company's revenue for Q4 2024 increased 24.0% year-over-year, with a notable reduction in net loss. Additionally, iRhythm holds $535.6 million in cash and marketable securities. Despite the positive outlook, the overall net loss for the year remains substantial, prompting scrutiny of future expense management and operational efficiency.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (in thousands, except per share data) (unaudited) Three Months Ended September 30, Nine Months Ended
iRhythm Technologies, Inc. reported a strong financial performance in the third quarter of 2024, with revenues up 18% year-over-year, amounting to $147.5 million. The company achieved a gross margin of 68.8% due to increased demand for its services and operational efficiencies. However, despite the revenue growth, iRhythm experienced a net loss of $46.2 million, largely driven by a $32.1 million charge from a technology licensing agreement. Additionally, operating expenses markedly increased, raising concerns about cost management even as the company expands its market presence and product offerings.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended June 30, Six Months Ended
iRhythm Technologies, Inc. reported a strong performance in its second quarter of 2024, with a revenue of $148 million, marking a 19.3% increase year-over-year. The company also announced improved gross margins of 69.9% and raised its full-year guidance for revenue and profitability. Notable operational achievements include preparations for launches in four European countries and ongoing advancements in manufacturing processes. However, the company reported an increased net loss and rising operating expenses, which could impact financial sustainability.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended
iRhythm Technologies reported a strong financial performance for Q1 2024, achieving $131.9 million in revenue, an 18.4% increase compared to Q1 2023. The company has also raised its revenue guidance for the full year to a range of $578 million to $588 million due to robust demand for its Zio services. However, the gross margin has decreased to 66.3%, and the net loss has increased to $45.7 million, which poses concerns regarding ongoing operational costs. Upcoming data presentations and collaborations highlight iRhythm's commitment to improving cardiac monitoring and integrating digital health solutions.
Read more →IRTCDealer name and address ] [March __], 2024 To: iRhythm Technologies, Inc. 699 8 th Street, Suite 600 San Francisco, CA 94103 Attention: Legal Department Re: [Base][Additional] Call Option Transaction The purpose of this
iRhythm Technologies, Inc. has entered into a call option transaction with a dealer, confirming terms of the agreement as outlined in a letter agreement. The transaction involves the issuance of Convertible Senior Notes due 2029, and the agreement is governed by ISDA standards. This confirmation includes various details such as trade dates, strike prices, and expiration terms, but does not indicate any immediate changes in company operations or outlook.
Read more →IRTCIRHYTHM PRICES UPSIZED OFFERING OF $575.0 MILLION OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2029 SAN FRANCISCO, MARCH 4, 2024 (GLOBE NEWSWIRE) iRhythm Technologies, Inc. ( iRhythm ) (NASDAQ: IRTC), a leading digital health c
iRhythm Technologies, Inc. has announced the pricing of its upsized offering of $575.0 million of 1.50% Convertible Senior Notes due 2029. The offering size was increased from a previously stated $450.0 million, reflecting strong institutional demand. The company plans to use the net proceeds for various purposes, including debt repayment and corporate growth activities. The sale is expected to close on March 7, 2024, subject to standard closing conditions, with an option for initial purchasers to acquire additional notes.
Read more →IRTC▼ -9.5%on this newsshared move
IRHYTHM ANNOUNCES PROPOSED OFFERING OF $450.0 MILLION OF CONVERTIBLE SENIOR NOTES SAN FRANCISCO, MARCH 4, 2024 (GLOBE NEWSWIRE) iRhythm Technologies, Inc. ( iRhythm ) (NASDAQ:IRTC), a leading digital health care company
iRhythm Technologies, Inc. announced a proposed offering of $450 million in convertible senior notes due in 2029. The offering is aimed at qualified institutional buyers and is subject to market conditions. Proceeds from the offering will be used for various corporate purposes, including the repayment of existing debt and potential share repurchases. An estimated $80.1 million is expected to repay outstanding indebtedness, while the remaining funds will be allocated toward general corporate activities, including research and development.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (In thousands, except per share data) (Unaudited) Three Months Ended December 31, Year Ended
iRhythm Technologies reported its Q4 and full-year 2023 financial results, showcasing a revenue increase of 17.7% in Q4, driven by heightened demand for its Zio services. However, the company experienced an increased net loss of $38.7 million during the quarter, up from $20.2 million the previous year, and a decline in gross margins. Looking ahead, iRhythm forecasts revenue growth for 2024 between $575 million and $585 million, despite the operational challenges reflected in higher expenses and losses.
Read more →IRTC▲ +7.3%on this news
iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, JANUARY 8, 2024 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc.
iRhythm Technologies announced preliminary fourth-quarter highlights and a business update at the 42nd Annual J.P. Morgan Healthcare Conference, showcasing their focus on organizational efficiency and financial sustainability. The company closed a five-year non-dilutive debt facility worth up to $150 million, which will be used to repay outstanding debt and support general corporate purposes. Executives expressed excitement about future growth driven by their innovative cardiac monitoring solutions. They also highlighted their commitment to enhancing patient care while navigating various risks associated with market uncertainties.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended September 30, Nine Months Ended
iRhythm Technologies reported a strong financial performance for Q3 2023, with revenues reaching $124.6 million, reflecting a 20% increase from the previous year. The company also raised its full-year revenue guidance to between $487.5 million and $490 million, citing robust growth in Zio services. However, the gross margin declined and net losses widened due to increased operating expenses. The launch of their next-generation Zio monitor and opening of a business services center in the Philippines are key operational highlights.
Read more →IRTCReconciliation of GAAP to Non GAAP Financial Information Three Months Ended December 31, Year Ended
iRhythm Technologies, Inc. reported strong financial results for Q4 and full year 2022, showcasing a significant revenue growth of 37.7% in Q4. Despite a net loss of $20.2 million for the quarter and a total annual loss of $116.2 million, the company achieved a positive adjusted EBITDA of $1.1 million in Q4. The report highlighted improvements in gross margins, driven by higher selling prices and operational efficiencies, while cash reserves increased to $213.1 million. Looking ahead, iRhythm projects revenue growth of 16% to 18% for 2023, indicating confidence in its ongoing strategy and market position.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, Adjusted EBITDA recon
iRhythm Technologies Announces Third Quarter 2022 Financial Results SAN FRANCISCO, November 1, 2022 - iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported f
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (Unaudited) (In thousands) Three Months Ended June 30, Six Months Ended June 30, Adjusted EBITDA reconciliation 2022 2021 2022 2021 Net
iRhythm Technologies Announces Second Quarter 2022 Financial Results SAN FRANCISCO, August 4, 2022 - iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the thre
Read more →IRTC▼ -8.9%on this news
IRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (Unaudited) (In thousands) Three months ended March 31, Adjusted EBITDA reconciliation 2022 2021 Net loss $ (50,609) $ (27,779) Income t
iRhythm Technologies Announces First Quarter 2022 Financial Results SAN FRANCISCO, May 5, 2022 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three m
Read more →IRTCiRhythm Technologies Announces Amendment to Term Loan Agreement Provides enhanced credit facility up to $100 million with favorable terms and facility maturity extended to March 2027
iRhythm Technologies Announces Amendment to Term Loan Agreement Provides enhanced credit facility up to $100 million with favorable terms and facility maturity extended to March 2027 SAN FRANCISCO, March 29, 2022 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital he
Read more →IRTC▼ -9.2%on this news
Document iRhythm Technologies Announces Kevin King to Retire from Board of Directors
iRhythm Technologies Announces Kevin King to Retire from Board of Directors SAN FRANCISCO, March 14, 2022 -- iRhythm Technologies, Inc. (NASDAQ IRTC) ("iRhythm"), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that Kevi
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) (In thousands) Three months ended December 31, Year ended
iRhythm Technologies Announces Fourth Quarter and Full Year 2021 Financial Results SAN FRANCISCO, February 23, 2022 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial re
Read more →IRTC▼ -6%on this news
IRHYTHM TECHNOLOGIES, INC. Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) (In thousands) Three Months Ended September 30, Nine Months Ended
iRhythm Technologies Announces Third Quarter 2021 Financial Results SAN FRANCISCO, November 4, 2021 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the t
Read more →IRTCDocument iRhythm Technologies Announces Changes to Its Board of Directors Karen Ling Appointed to the Board Raymond Scott to Retire
iRhythm Technologies Announces Changes to Its Board of Directors Karen Ling Appointed to the Board Raymond Scott to Retire SAN FRANCISCO, October 12, 2021 -- iRhythm Technologies, Inc. (NASDAQ IRTC) ("iRhythm"), a leading digital healthcare solutions company focused on the adva
Read more →IRTC▲ +35%on this news
Document iRhythm Technologies Names Quentin Blackford President and Chief Executive Officer Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Financial Execution with High Growth Companie
iRhythm Technologies Names Quentin Blackford President and Chief Executive Officer Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Financial Execution with High Growth Companies SAN FRANCISCO, September 13, 2021 -- iRhythm Technologies, Inc. (
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) (In thousands) Three Months Ended June 30, Six Months Ended
iRhythm Technologies Announces Second Quarter 2021 Financial Results SAN FRANCISCO, August 5, 2021 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the th
Read more →IRTCThe Company also reiterated its second quarter 2021 guidance of approximately 4% sequential volume growth over the first quarter of 2021 and operating expenses to be approximately flat compared to the first quarter 2021.
iRhythm Technologies Announces Leadership Transition President and CEO Michael Coyle Steps Down Due to Personal Matters Douglas Devine to Serve as Interim CEO While Search for Permanent CEO is Conducted SAN FRANCISCO, June 1, 2021 - iRhythm Technologies, Inc. (NASDAQ IRTC), a
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) (In thousands) Three Months Ended
iRhythm Technologies Announces First Quarter 2021 Financial Results SAN FRANCISCO, May 6, 2021 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three
Read more →IRTCThe first quarter 2021 financial results included in this release are preliminary and therefore subject to change. Webcast and Conference Call Information iRhythm will host a conference call today
iRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas's Updated Rate Publication and Provides Commentary on Results for the First Quarter 2021 SAN FRANCISCO, April 12, 2021 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital healt
Read more →IRTCiRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas Recent Rate Publication
iRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas Recent Rate Publication SAN FRANCISCO, January 29, 2021 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac
Read more →IRTCcardioverter defibrillator, and cardiac resynchronization businesses. He also led the company's Daig Catheter division in an earlier president role. Additionally, Mr. Coyle held numerous leadership positions at Eli Lilly
iRhythm Technologies President and CEO Kevin King to Retire Michael Coyle Joins Company as President and CEO Effective January 12, 2021 SAN FRANCISCO, December 14, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the ad
Read more →IRTCiRhythm Technologies Comments on Centers for Medicare and Medicaid Services 2021 Medicare Physician Fee Schedule Final Rule Webcast Scheduled for
iRhythm Technologies Comments on Centers for Medicare and Medicaid Services 2021 Medicare Physician Fee Schedule Final Rule Webcast Scheduled for December 2, 2020 at 5 30 am PT 8 30 am ET SAN FRANCISCO, December 2, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading dig
Read more →IRTCLeigh Salvo Saige Smith (415) 937-5404 (262) 289-7065 investors irhythmtech.com irhythm highwirepr.com
ZIO BY IRHYTHM DETECTS PREVIOUSLY UNDIAGNOSED ATRIAL FIBRILLATION AND HELPS TO PREVENT HOSPITALIZATIONS, STROKE, AND DEATH AS A RESULT a.Three-Year Study Results Presented at 2020 American Heart Association Scientific Sessions b.Zio Supports Better Healthcare Utilization Rates
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) (In thousands) Three Months Ended September 30, Net loss $ (4,677) Income tax provision 105 Depreciation and Amortization 1,702 Interes
iRhythm Technologies Announces Third Quarter 2020 Financial Results SAN FRANCISCO, November 5, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the t
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended June 30, Six Months Ended
iRhythm Technologies Announces Second Quarter 2020 Financial Results SAN FRANCISCO, August 6, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the th
Read more →IRTCiRhythm Technologies Comments on the Centers for Medicare and Medicaid Services 2021 Proposed Physician Fee Schedule
iRhythm Technologies Comments on the Centers for Medicare and Medicaid Services 2021 Proposed Physician Fee Schedule SAN FRANCISCO, August 4, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac c
Read more →IRTCiRhythm Technologies Announces CFO Transition
iRhythm Technologies Announces CFO Transition SAN FRANCISCO, June 4, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today that Douglas Devine has been appointed Chief Financi
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended
iRhythm Technologies Announces First Quarter 2020 Financial Results SAN FRANCISCO, May 7, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three
Read more →IRTCiRhythm Technologies Announces the Appointment of Renee Budig to its Board of Directors
iRhythm Technologies Announces the Appointment of Renee Budig to its Board of Directors SAN FRANCISCO, April 23, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the appo
Read more →IRTCiRhythm Technologies Announces Update on COVID-19 Impact and Response Announces Preliminary Revenue Results for First Quarter of 2020 Withdraws 2020 Financial Guidance
iRhythm Technologies Announces Update on COVID-19 Impact and Response Announces Preliminary Revenue Results for First Quarter of 2020 Withdraws 2020 Financial Guidance SAN FRANCISCO, April 9, 2020 -- iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care soluti
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Consolidated Statements of Operations (In thousands, except share and per share data) Three Months Ended December 31, Year Ended
iRhythm Technologies Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Financial Outlook SAN FRANCISCO, February 27, 2020 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancem
Read more →IRTCiRhythm Technologies Files Quarterly Report on Form 10-Q for Third Quarter 2019 and Updates Guidance for Full Year 2019
iRhythm Technologies Files Quarterly Report on Form 10-Q for Third Quarter 2019 and Updates Guidance for Full Year 2019 Conference Call Scheduled for Today at 8:30 AM ET/5:30 AM PT SAN FRANCISCO, December 23, 2019 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital h
Read more →IRTCiRhythm Technologies Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
iRhythm Technologies Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q SAN FRANCISCO, November 19, 2019-- iRhythm Technologies, Inc. (NASDAQ: IRTC), announced today that it received a standard notification letter (the "Notice") from
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended
iRhythm Technologies Announces Third Quarter 2019 Financial Results SAN FRANCISCO, November 5, 2019-- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the t
Read more →IRTCiRhythm Announces Collaboration with Verily to Develop Health Management Solutions for Atrial Fibrillation Patients
iRhythm Announces Collaboration with Verily to Develop Health Management Solutions for Atrial Fibrillation Patients SAN FRANCISCO, September 4, 2019 iRhythm Technologies, Inc. (NASDAQ: IRTC) today announced a collaboration with Verily, an Alphabet company, focused on the devel
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data) Three Months Ended
iRhythm Technologies Announces First Quarter 2019 Financial Results Raises Guidance for Full Year 2019 SAN FRANCISCO, May 7, 2019 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today repo
Read more →IRTCiRhythm Technologies Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Financial Outlook
iRhythm Technologies Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Financial Outlook SAN FRANCISCO, February 12, 2019 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancem
Read more →IRTCirtc-ex991_17.pptx.htm J.P. Morgan Healthcare Conference January 2019 Certain data in this presentation was obtained from various external sources, and neither "iRhythm" or the "Company" nor its affiliates or representat
J.P. Morgan Healthcare Conference January 2019 Certain data in this presentation was obtained from various external sources, and neither "iRhythm" or the "Company" nor its affiliates or representatives has verified such data with independent sources. Accordingly, neither the Com
Read more →IRTCiRhythm Technologies Announces Third Quarter Financial Results
iRhythm Technologies Announces Third Quarter Financial Results SAN FRANCISCO, October 30, 2018-- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three
Read more →IRTCiRhythm Technologies Announces Second Quarter Financial Results
iRhythm Technologies Announces Second Quarter Financial Results SAN FRANCISCO, August 1, 2018-- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three m
Read more →IRTCiRhythm Technologies Names Karim Karti as Chief Operating Officer
iRhythm Technologies Names Karim Karti as Chief Operating Officer SAN FRANCISCO - June 27, 2018 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the appointment of Karim Karti
Read more →IRTCiRhythm Technologies Appoints UCLA and Cedars-Sinai Professor C. Noel Bairey Merz, M.D. to its Board of Directors
iRhythm Technologies Appoints UCLA and Cedars-Sinai Professor C. Noel Bairey Merz, M.D. to its Board of Directors SAN FRANCISCO - April 10, 2018 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac car
Read more →IRTCiRhythm Technologies Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Full Year 2018 Financial Outlook
iRhythm Technologies Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Full Year 2018 Financial Outlook SAN FRANCISCO, February 14, 2018 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancem
Read more →IRTCiRhythm Technologies Announces Third Quarter 2017 Financial Results and Raises Guidance for Full Year 2017
iRhythm Technologies Announces Third Quarter 2017 Financial Results and Raises Guidance for Full Year 2017 SAN FRANCISCO, November 1, 2017 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, t
Read more →IRTCiRhythm Technologies Names UC Berkeley Faculty Member Bruce G. Bodaken and Duke University Chancellor Emeritus Ralph Snyderman, M.D. to its Board of Directors
iRhythm Technologies Names UC Berkeley Faculty Member Bruce G. Bodaken and Duke University Chancellor Emeritus Ralph Snyderman, M.D. to its Board of Directors SAN FRANCISCO - July 19, 2017 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions compa
Read more →IRTCiRhythm Technologies Announces First Quarter 2017 Financial Results Raises Guidance for Full Year 2017
iRhythm Technologies Announces First Quarter 2017 Financial Results Raises Guidance for Full Year 2017 SAN FRANCISCO, May 3, 2017 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today repo
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data) Three Months Ended December 31, Twelve Months Ended
iRhythm Technologies Announces Fourth Quarter and 2016 Financial Results and Provides Full Year 2017 Financial Outlook SAN FRANCISCO, February 15, 2017 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of car
Read more →IRTCiRhythm Technologies Announces Third Quarter 2016 Financial Results and Provides Full Year 2016 Financial Outlook
iRhythm Technologies Announces Third Quarter 2016 Financial Results and Provides Full Year 2016 Financial Outlook SAN FRANCISCO, December 5, 2016 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac c
Read more →Competitive Position
How IRTC ranks across every disease it competes inCompetitive Position is a premium feature
See how IRTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial